Abstract:Objective: To compare the antibody persistence 5 years after primary immunization with 5 μg and 10 μg recombinant hepatitis B vaccine (HepB) among newborns with normal and high response. Methods: Newborns who completed three doses of 5 μg HepB made by recombinant dexyribonucleic acid technique in Saccharomyces (HepB-SC) or 10 μg HepB made by recombinant dexyribonucleic acid technique in Hansenula polymorpha (HepB-HP) were recruited. Standardized questionnaire was used and blood samples were collected 1-6 months (T(0)) and five years (T(1)) after the third dose respectively. The titer of anti-HBs was detected by chemiluminescence microparticle imunoassay (CMIA). Those who achieved normal or high antibody response (anti-HBs titer ≥100 mIU/ml) were included in the study and the positive rate (≥10 mIU/ml) and titer of anti-HBs at T(1) were compared between 5 μg HepB group and 10 μg HepB group. Multivariable analysis was conducted to identify the independent factors associated with the antibody persistence. Results: The positive rate of anti-HBs at T(1) was 49.92% (943/1 883) and 75.92% (1 135/1 495) respectively in 5 μg HepB group and 10μg HepB group, the difference was significant (χ(2)=237.75, P<0.001). The anti-HBs geometric mean concentrations at T(1) were 10.23 mIU/ml (95%CI: 9.38-11.16) and 28.91 mIU/ml (95%CI: 26.65-31.35) in the two groups respectively, the difference was also significant (F=280.36, P<0.001). Among those whose anti-HBs titer was<10 mIU/ml at T(1), the distributions of anti-HBs titer were significantly different between 5 μg HepB group and 10 μg HepB group (χ(2)=39.75, P<0.001). The multivariable analysis showed that dosage of HepB was independently associated with both positive rate and titer of anti-HBs at T(1) after excluding the other factors[P<0.001, OR=1.44 (95%CI: 1.20-1.73); P<0.001, β=0.27 (95%CI: 0.14-0.40)]. Conclusion: Five year anti-HBs persistence after primary immunization with 10 μg HepB might be better than that after primary immunization with 5 μg HepB among infants who achieved normal or high anti-HBs response after primary HepB immunization.

Comparative Long Term Immunogenicity of Two Recombinant Hepatitis B Vaccines and the Effect of a Booster Dose Given After Five Years in a Low Endemicity Country

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

The long-term efficacy of recombinant hepatitis B vaccines for children

[Long-Term Efficacy Study of Hepatitis B Vaccination in Newborns--results of 11 Years' Follow-Up].

Long-Term Efficacy And Immune Memory Of Neonatal Recombinant Hepatitis B Vaccination In Adolescents Aged 13-14 Years

Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose

The effects of booster vaccination of hepatitis B vaccine on anti-HBs negative children 11-15 years after primary vaccination

Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China

Comparison of Long-Term Immunogenicity (23 Y) of 10 Μg and 20 Μg Doses of Hepatitis B Vaccine in Healthy Children

Effects of hepatitis B vaccine boosters in different levels of epidemic areas on anti-HBs-negative children after primary vaccination

[Comparison of Antibody Persistence after Primary Immunization with 5 Μg and 10 Μg Recombinant Hepatitis B Vaccine among Newborns with Normal and High Response: a Five-Year Following-Up].

Modeling Long-Term Persistence after 8 Years of Hepatitis B Booster Vaccination in 5- to 15-Year-old Children

Long-term Evaluation of Immune Efficacy among Newborns 16 Years after HBV Vaccination

An observation on the long-term efficacy of recombinant hepatitis B vaccines among the newborns

Evaluation of antibody persistence after a four-dose primary hepatitis B vaccination and anamnestic immune response in children under 6 years

SIX-YEAR EFFICACY OF HEPATITIS B REVACCINATION: ADOUBLE-BLIND, PLACEBO-CONTROLLED AND RANDOMIZED FIELD TRIAL

Long-Term T-Cell-Mediated Immunologic Memory to Hepatitis B Vaccine in Young Adults Following Neonatal Vaccination.